Treating Blood Cancers

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC Recorded on December 18, 2025 Lore Gruenbaum, PhD Chief Scientific Officer & Senior Vice President of Research Blood Cancer United Washington, DC Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Resources for Patients

Raymond Mailhot, MD, MPH, University of Miami, Miami, FL Recorded on December 2, 2025 Raymond Mailhot, MD, MPH Department of Radiation Oncology University of Miami Miami, FL Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional EducationBlood Cancer United Medical Debt Case Management Program for PatientsBlood Cancer United Additional Resources for Patients

Paul J. Hampel, MD, Mayo Clinic, Rochester, MN Recorded on November 4, 2025 Paul J. Hampel, MD Assistant Professor of Medicine Division of Hematology, Department of Medicine Mayo Clinic Rochester, MN In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, […]

Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 23, 2025 Michael J. Mauro, MD Director, Chronic Myeloid Leukemia Program Professor of Medicine, Leukemia Service Memorial Sloan Kettering Cancer Center New York, NY Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center […]

Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA Recorded on September 25, 2025 Rahul Banerjee, MD, FACP Assistant Professor Fred Hutchinson Cancer Center Seattle, WA In this episode, Dr. Rahul Banerjee from Fred Hutchinson Cancer Center in Seattle, WA, discusses the evolving role of measurable residual disease (MRD) in hematologic malignancies. He explores […]

Ann Collins, PA, Blood Cancer United, Washington, DC, Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC, Sarah K. Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA Recorded on September 9, 2025 Ann Collins, PA Project Leader, Pediatric Acute Leukemia Master Clinical Trial (PedAL) Blood Cancer United Washington, DC Kelly Laschinger, MSN, RN, […]

Catherine Lai, MD, MPH, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, PA Recorded on June 27, 2025 Catherine Lai, MD, MPH Associate Professor Physician Leader, Leukemia Clinical Research Unit University of Pennsylvania Perelman Center for Advanced Medicine Philadelphia, PA In this episode, Dr. Catherine Lai, from the University of Pennsylvania’s Perelman Center for Advanced Medicine, joins us to discuss the current landscape of adult acute lymphoblastic leukemia (ALL) treatment. She highlights recent advances in frontline and relapsed therapies, the critical role of measurable residual disease (MRD), and the use of immunotherapy and targeted treatments. Dr. Lai further explores transplant considerations, management of side effects, and tailored approaches for B-cell and T-cell ALL. She also emphasizes patient-centered care, including strategies for end-of-life discussions and shared decision-making. Tune in today for expert insights and practical takeaways on the evolving future of ALL care!

Uma Borate, MBBS, MS, The Ohio State University, Cleveland, OH Recorded on May 27, 2025 Uma Borate, MBBS, MS Associate Professor, Division of Hematology Acute Leukemia Clinical Research Disease Group Leader The Ohio State University Cleveland, OH What’s changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don’t miss this dynamic conversation packed with expertise and hope for the future of AML!

Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH Recorded on May 13, 2025 Aaron Gerds, MD, MS Associate Professor of Medicine Cleveland Clinic Lerner College of Medicine Case Western Reserve University School of Medicine Medical Director Case Comprehensive Cancer Center Clinical Research Office Cleveland, OH In this episode, Dr. Aaron Gerds from the Cleveland Clinic explores the intricacies of Myeloproliferative Neoplasms (MPNs), from diagnosis and monitoring to treatment goals and the latest therapeutic advances. Dr. Gerds discusses emerging therapies, the significance of clinical trials, strategies for managing side effects and long-term effects, and valuable resources for healthcare professionals, patients, and families. Tune in today for expert insights on MPNs! This episode is supported by GSK plc and Karyopharm Therapeutics.

Tessa Faye Flores, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY Recorded on April 24, 2025 Tessa Faye Flores, MD Medical Director, Cancer Screening and Survivorship Roswell Park Comprehensive Cancer Center Buffalo, NY We are pleased to celebrate the 100th episode of Treating Blood Cancers with Dr. Tessa Flores from Roswell Park Comprehensive Cancer Center in Buffalo, New York, as she shares insights into survivorship care. In this episode, Dr. Flores explores the different phases of survivorship and the psychosocial challenges that accompany each stage. She highlights the vital role of a collaborative care team, including primary care practitioners, in supporting survivors of cancer to achieve and maintain a healthy post-treatment life. As the number of survivors continues to grow, the focus on long-term wellness becomes increasingly important. Dr. Flores emphasizes, “A tenet of survivorship care is preventive care”. Tune in for this special episode and join the conversation today! This episode is supported by Genentech, A Member of the Roche Group. Additional Episodes on Survivorship Care:

Mikkael A. Sekeres, MD, MS, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL Recorded on April 17, 2025 Mikkael A. Sekeres, MD, MS Chief, Division of Hematology Professor of Medicine Sylvester Comprehensive Cancer Center University of Miami Miami, FL Join us with Dr. Mikkael Sekeres of the University of Miami Sylvester Comprehensive Cancer Center as he explores the complexities of diagnosing and treating Myelodysplastic Syndromes (MDS), including “watch and wait.” Through case-based discussion, he highlights advances in high-risk MDS management, from novel targeted therapies to stem cell transplantation and clinical trials. Dr. Sekeres also shares strategies for managing side effects and emphasizes the importance of multidisciplinary care in improving patient outcomes. Tune in to gain valuable insights on MDS today!

Jeffrey Magee, MD, PhD, Washington University School of Medicine, St. Louis, MO Recorded on April 3, 2025 Jeffrey Magee, MD, PhD Elizabeth H. and James S. McDonnell III Professor of Pediatrics Director, McDonnell Pediatric Cancer Center Division of Pediatric Hematology and Oncology Washington University School of Medicine St. Louis, MO In this episode, we sit down with Dr. Jeffrey Magee from the McDonald Pediatric Cancer Center at the Washington University School of Medicine in St. Louis to discuss the evolving landscape of pediatric blood cancers. Reflecting on his work, Dr. Magee shares, “One of the things I really love about the job is that it operates right at the interface between the science and the professional practice of medicine.” He examines groundbreaking advances bringing new hope to children and their families, from novel therapies and CAR T-cell therapy to the crucial role of clinical trials. Dr. Magee also speaks candidly about the challenges of delivering difficult news and shares compassionate strategies for supporting families through their toughest moments. Join us for this insightful and informative conversation on the future of pediatric blood cancer care today!

Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN Recorded on March 18, 2025 Angela Dispenzieri, MD Consultant, Division of Hematology Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine and Pathology Mayo Clinic Rochester, MN Join us as we dive into in the complex care of amyloid and myeloma with Dr. Angela Dispenzieri from Mayo Clinic Rochester, Minnesota. She explains the diagnosis and explores the differences between amyloid and myeloma. Discussion on treatment strategies for complex cases, side effects of therapies, and difficult conversations with patients, provide practical information on patient care. Tune in today to learn more about the complexities of myeloma. This episode is supported by GSK plc.

Guy Maytal, MD, Forge Health and Weill Cornell Medicine, New York, NY Recorded on February 20, 2025 Guy Maytal, MD Chief Medical Officer, Forge Health White Plains, NY Clinical Assistant Professor of Psychiatry, Weill Cornell Medicine New York, NY In this episode, Dr. Guy Maytal, from Forge Health and Weill Cornell Medicine in New York, explores burnout and wellness in healthcare professionals, highlighting the difference between burnout and compassion fatigue. He shares valuable insights on recognizing these issues, while emphasizing the importance of connection, resilience, and self-care in preventing and overcoming burnout. Dr. Maytal also offers practical strategies for institutions to better support healthcare professionals. Tune in for the latest insights on healthcare professional wellness today!

Timothy Pearman, PhD, ABPP, Northwestern University Feinberg School of Medicine, Chicago, IL Recorded on February 6, 2025 Timothy Pearman, PhD, ABPP Director, Supportive Oncology Robert H. Lurie Comprehensive Cancer Center Professor, Department of Medical Social Sciences and Psychiatry & Behavioral Sciences Northwestern University Feinberg School of Medicine Chicago, IL Join us for an insightful episode featuring Dr. Timothy Pearman from Northwestern University, as he explores the critical role of caregivers and care partners to a patient’s healthcare team. Dr. Pearman discusses the challenges caregivers face, including burnout, relationship stress, and issues surrounding sex and intimacy. He also offers effective communication strategies to address these challenges and shares ways healthcare professionals can better educate and support caregivers. Tune in to this informative podcast for valuable insights and resources for caregivers! This episode is supported by Genentech, A Member of the Roche Group.

Jason Westin, M.D., MS, FACP, MD Anderson Cancer Center, Houston, TX Recorded on January 21, 2025 Jason Westin, M.D., MS, FACP Professor, Department of Lymphoma & Myeloma Lead, Lymphoma & Myeloma Service Line Director, Lymphoma Clinical Research Section Chief, Aggressive and Indolent Lymphoma MD Anderson Cancer Center Houston, TX In this episode, Dr. Jason Westin from MD Anderson Cancer Center in Houston, Texas explores CAR T-cell therapy, covering both current and emerging indications. He highlights the educational needs of patients and caregivers, as well as the essential role of community and academic collaboration before and after treatment. Dr. Westin also discusses the use of minimal/measurable residual disease (MRD) in treatment planning, future directions of CAR-T, and ongoing clinical trials. Tune in to stay up-to-date on the latest advancements in CAR T-cell therapy! This episode is supported by Allogene Therapeutics, Bristol Myers Squibb, Johnson& Johnson & Legend Biotech, and Kite, a Gilead Company.

Jaehyuk (Jae) Choi, MD, Northwestern University Feinberg School of Medicine, Chicago, IL Recorded on January 7, 2025 Jaehyuk (Jae) Choi, MD Jack W. Graffin Associate Professor of Dermatology and of Biochemistry and Molecular Genetics Northwestern University Feinberg School of Medicine Chicago, IL In this episode, Dr. Jaehyuk Choi from Northwestern University, explores Cutaneous T-Cell Lymphoma (CTCL), covering key diagnostic tools, emerging therapies, and the importance of a multidisciplinary team approach. He delves into effective symptom management, including the psychosocial impact of pruritus, and discusses the latest ongoing research. Additionally, Dr. Choi highlights disparities in diagnosis, treatment access, and patient outcomes. Tune in today to gain valuable insights on this complex diagnosis! This episode is supported by Kyowa Kirin, Inc.

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 19, 2024 Lee Greenberger, PhD Chief Scientific Officer and SVP The Leukemia & Lymphoma Society Rye Brook, NY In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide information presented at the 66th American Society of Hematology (ASH) Annual Meeting, including updates in myeloma, leukemia, and lymphoma. Dr. Greenberger also discusses updates in blood cancer therapies, including nutrition, CAR T-cell therapy, and bispecifics. Tune in today! This episode is supported by Autolus Therapeutics.

Celeste Bello, MD, Moffitt Cancer Center, Tampa, FL Recorded on November 21, 2024 Celeste Bello, MD Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL Join us as we dive into bispecific antibodies with Dr. Celeste Bellow from Moffitt Cancer Center, exploring their mechanisms of action, current indications in lymphoma, and strategies for patient selection and administration. Dr. Bello also discusses side effects, management strategies, and emerging trends in bispecific therapies. Tune in today to learn more!

Lynn Gooden, BSN, RN, ONN-CG, Community Health Network MD Anderson Cancer Center, Indianapolis, IN and Cassie Osborne, MSN, RN, OCN, ONN-CG, Community Health Network MD Anderson Cancer Center, Indianapolis, IN Recorded on November 14, 2024 Lynn Gooden, BSN, RN, ONN-CG Oncology Navigation and Survivorship Manager Oncology Navigation Community Health Network MD Anderson Cancer Center Indianapolis, IN Cassie Osborne, MSN, RN, OCN, ONN-CG Oncology Nurse Navigator Oncology Navigation-Hematology/Sarcoma/Brain/Skin Community Health Network MD Anderson Cancer Center Indianapolis, IN Join us for this important episode, as Lynn Gooden and Cassie Osborne, nurses from the Community Health Network MD Anderson Cancer Center in Indianapolis, discuss mental health challenges faced by survivors of cancer, including the impact of long-term and late effects. They explore how a multidisciplinary team can address both physical and psychosocial needs, and caregiver involvement in decision-making and support. Resources are also highlighted for healthcare professional education, along with support resources for survivors and caregivers to enhance survivorship. Tune in to today for this insightful discussion! This episode is supported by Genentech, A Member of the Roche Group.